Radboud University Medical Center is Conducting Safety Evaluation of MediSieve’s Magnetic Haemofiltration System for the Treatment of Acute Hyperinflammation.

LONDON, July 1, 2022 -- MediSieve today announced that the first volunteer had been enrolled in Phase 1 clinical study evaluating its Magnetic Haemofiltration System, a groundbreaking platform therapy which physically removes specific clinical targets from the bloodstream, as a potential treatment for IL-6-driven acute hyperinflammation.  The System demonstrated a favourable safety and tolerability profile. The clinical study is being conducted at the Radboud University Medical Center, a leading Dutch medical institution. Prof. Peter Pickkers and Dr. Matthijs Kox, world experts on First-In-Man trials, are leading the study.

The Phase 1 study is a non-comparative study, evaluating the safety and initial performance of the MediSieve delivery system in healthy volunteers. The study is expected to enrol 8 female and male volunteers. Once the trial is completed, the data will be published in peer-reviewed scientific journals.

“This phase 1 trial is the first step in evaluating the use of MediSieve’s Magnetic Haemofiltration System for treatment of IL-6 driven hyperinflammation,” said Dr Matthijs Kox, lead investigator on the clinical trial. “The ability to selectively remove IL-6 and other targets without systemic drug exposure opens the door to treatment of a wide range of indications including ARDS, pancreatitis and post cardiac surgery.”

MediSieve’s pivotal IL-6 product is designed to treat acute cases of IL-6-driven hyperinflammation in patients with Cytokine storm, AKI, ARDS, CRS, Pancreatitis, Cardiac Surgery and others. High mortality and morbidity rates among patients with increased IL-6 levels place a considerable burden on healthcare systems around the world. Currently, systemic IL-6 inhibitors are the most popular form of treatment. However, because of their long-term immunosuppression, which makes patients more susceptible to both the initial infection and a later infection, these medications are inappropriate for the treatment of acute hyperinflammation. MediSieve's System allows for the selective elimination of hazardous compounds without the aforementioned side effects.

"This is a huge step for the company, and one that we have been working towards for many years,” said Cristina Blanco-Andujar, Ph.D., Chief Technology Officer of MediSieve. “We have for the first time tested our technology in humans and seen the dream of a founder transformed into reality. We are really excited to continue this clinical study and bring the benefits of Magnetic Haemofiltration to patients .

About MediSieve

MediSieve is a biotech company, that has developed “Magnetic Haemofiltration”, a drug-device platform for treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From hyperinflammation to severe malaria to leukaemia and viral infections, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk

Sort by: Newest First Oldest First Most Popular Most unliked